Community/Retail

The guidelines recommend using molecular tests that deliver results in 15-60 minutes instead of rapid-influenza diagnostic tests (RIDTs), which produce quick results but can be falsely negative in at least 30% of outpatients with influenza.

This vaccine does not constitute a primary immunization series against pertussis.

Patients who transitioned to COT, which is defined as daily or near-daily use of opioids for at least 90 days, had total health care expenditures that were $4607 higher than those of patients who did not continue long-term opioid use.

The weekly report is also available through an online, interactive map, which allows anyone to search and find information regarding the most current state of influenza in their community.

Under the settlement and license agreement, Neos has granted Teva the right to manufacture and market its generic version of Cotempla XR-ODT® under the Teva ANDA beginning on July 1, 2026, or earlier under certain circumstances.

This is the only vaccination approved in the United States to prevent this bacterial disease.

We analyzed the data, and these are the articles our audience was most interested in reading online this year.

According to the indictment, from May 2014 to September 2016, the involved parties allegedly recieved kickbacks for the referral of TRICARE and DOL beneficiaries to obtain expensive compound drugs.

Opioids were involved in over two-thirds of overdose deaths in 2017.

The FDA has approved tagraxofusp-erzs (Elzonris, Stemline Therapeutics) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, aged 2 years and older.

Ravulizumab (Ultomiris, Alexion) is the first long-acting complement inhibitor approved for the treatment of paroxysmal nocturnal hemoglobinura.

Cigna recently announced the completion of its $54-billion acquisition of Express Scripts.

The FDA has approved calaspargase pegol-mknl (Asparlas, Servier Pharmaceuticals) as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Swisslog Healthcare's Relay, which will deliver medications and supplies, has the potential to assist staff members with daily tasks and deter drug diversion.

The National Hispanic Pharmacists Association was launched by the National Hispanic Health Foundation with public and private sector partners.

Officials with the FDA have approved olaparib (Lynparza, AstraZeneca and MSD) for the maintenance treatment of adult patients with BRCA-mutated advanced ovarian cancer.

Although there are some advantages and disadvantages to both routes of antibiotic administration, several factors must be considered when determining the best antibiotic delivery method for the patient, including cost, effort of administration, and safety risks.

The FDA granted an accelerated approval to pembrolizumab (Keytruda, Merck) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.

With the holiday season in full swing, managing your health might be the last thing on your mind.

The program launched by the Baltimore-based organizations is the first of its kind to leverage video technology and a public health practice known as Directly Observed Therapy, or DOT.

Ed Cohen discusses platform integration in the pharmacy.

In 2019, you can change your destiny, or you can maintain the status quo. You have a choice: become a drone or remain a dinosaur.

Prucalopride (Motegrity, Shire) is the only serotonin-4 receptor agonist approved for adults with Chronic Idiopathic Constipation.

Influenza vaccinations among patients with diabetes rose by 20% when they were notified about scheduling their flu shot, according to a new study.

Despite the completion of CVS Health’s purchase of Aetna in November, the company continues to be challenged over the merger’s potentially harmful effect on consumers and smaller competitors.

The FDA has approved trastuzumab-pkrb (Herzuma, Celltrion) as a biosimilar to trastuzumab (Herceptin, Genentech) for the treatment of HER2-overexpressing breast cancer.

Officials with the FDA have approved romiplostim (NPLATE, Amgen) for the treatment of immune thrombocytopenia (ITP) in pediatric patients aged 1 year and older.